The deal, which is anticipated to complete in January 2013, is subject to certain closing conditions.
Bio-Rad life science group president Brad Crutchfield said, "With this acquisition, Bio-Rad will have access to a comprehensive catalog of antibodies allowing us to better serve our customers by offering total assay solutions that can be validated on our research platforms for western blotting, multiplex protein expression, ELISA, and cell sorting."
AbD Serotec manufactures and offers antibodies, kits, and accessories. Bio-Rad manufactures and distributes life science research and clinical diagnostic products.